×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Company: Dopamine D3 and D4 Receptor Selective Agonists for Parkinson
company
507 words
KG: dopamine
2026-03-31
section:companies
kind:company
state:published
Contents
Dopamine D3 and D4 Receptor Selective Agonists for Parkinson's Disease
Knowledge Graph
Related Hypotheses (30)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.38
SASP-Mediated Complement Cascade Amplification
Score: 0.70
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Transcriptional Autophagy-Lysosome Coupling
Score: 0.66
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.62
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Multi-Modal Stress Response Harmonization
Score: 0.60
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.59
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
Microbial Inflammasome Priming Prevention
Score: 0.58
PARP1 Inhibition Therapy
Score: 0.58
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.56
Smartphone-Detected Motor Variability Correction
Score: 0.56
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56
Circadian Clock-Autophagy Synchronization
Score: 0.55
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.53
Show 25 more
Related Analyses (30)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Show 25 more
Related Experiments (30)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
Show 25 more
See Also (15)
Alzheimer Indonesia
institution · KG edge: activates
Amyloid-Related Imaging Abnormalities (ARIA)
entity · KG edge: activates
acetylcholine
general · KG edge: co_discussed
ALS Therapeutic Landscape — Programs by Phase and Modal
disease · Pages share 3 hypotheses
Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 3 hypotheses
vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 3 hypotheses
VEGF Signaling and Cerebral Angiogenesis in Neurodegene
mechanism · Pages share 3 hypotheses
Vagus Nerve Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses
Ubiquitin-Proteasome System Dysfunction in Neurodegener
mechanism · Pages share 3 hypotheses
ubiquitin-proteasome-dysfunction-neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
mechanism · Pages share 3 hypotheses
Therapeutic Targets in Neurodegeneration
mechanism · Pages share 3 hypotheses
Tertiary Lymphoid Organs in Neurodegeneration
mechanism · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (12 edges)
dopamine
regulates
neuronal uptake
dopamine
treats
diabetic retinal neurodegeneration
dopamine
activates
NRF2
dopamine
regulates
GPX4
dopamine
loss_affects
neuron
dopamine
loss_affects
SNCA
dopamine
loss_affects
Alzheimer
dopamine
loss_affects
Parkinson
dopamine
loss_affects
neurodegeneration
dopamine
loss_affects
substantia nigra